• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Peripartum Cardiomyopathy – Is It Safe to Attempt Another Pregnancy?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Although relatively rare, the incidence of peripartum appears to be increasing
  • Clinical course is variable from full recovery to up to a 30% mortality rate
  • Recommendations tend toward discouraging pregnancy due to risk of recurrence
  • With improving care and technology, more women are surviving and robust data on risks for future pregnancy are limited
  • Codsi et al. (Obstetrics & Gynecology, 2018) examined subsequent pregnancies of women with peripartum cardiomyopathy

METHODS:

  • Retrospective cohort study
  • Participants: All pregnant patients with prior peripartum cardiomyopathy defined as
    • Development of cardiac failure in the last month of pregnancy or within 5 months of delivery
    • Absence of an identifiable cause of cardiac failure
    • Absence of recognizable structural heart disease before the last month of pregnancy, and
    • Left ventricular (LV) systolic dysfunction with an LV ejection fraction (LVEF) <45%
  • Maternal and neonatal outcome data were abstracted
  • All echocardiography examinations were individually reviewed

RESULTS:

  • Data was collected for 25 patients with prior peripartum cardiomyopathy
  • 60% of index pregnancies had a hypertensive disorder of pregnancy
    • Three (12%) patients with gestational hypertension, nine (36%) with preeclampsia, and three (12%) with confirmed eclampsia
  • 12.1% of patients had a hypertensive disorder of pregnancy in subsequent pregnancies
  • All subjects except one had recovered LV function (ejection fraction 50% or greater) before the subsequent pregnancy
  • 43 subsequent pregnancies were identified with
    • 6 (14.0%) miscarriages
    • 4 (9.3%) terminations
    • 33 (76.7%) live births
  • The rate of peripartum cardiomyopathy relapse was 20.9%
    • Median LVEF nadir in patients with relapse was 43% (range 35-45%)
    • None had LVEF decline to the level of their index pregnancy
    • All patients with relapse recovered LV function within a median of 1 month
  • No cardiac arrests or deaths were observed
  • Median gestational age at delivery for all live births in subsequent pregnancies was 39.0 weeks (range 36 6/7-41 3/7 weeks)

CONCLUSION:

  • Patients with prior peripartum cardiomyopathy who recover LV function are at risk for a minor decrease in LV ejection fraction during future pregnancies
  • Neonatal and maternal outcomes are very favorable
  • Authors suggest the results of this study are encouraging, although further data would be required to determine optimal management in more diverse populations

Learn More – Primary Sources:

Subsequent Pregnancy Outcomes in Patients With Peripartum Cardiomyopathy 

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

How Common is Sudden Cardiac Arrest During Participation in Competitive Sports?
PURE Study Results – Carbs vs Fat Intake to Reduce Cardiovascular Morbidity and Mortality?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site